Description
RABIMEXA-LSR combines Rabeprazole Sodium I.P. 20 mg in an enteric-coated formulation with Levosulpiride 75 mg in a sustained-release formulation. Rabeprazole reduces gastric acid secretion, while Levosulpiride supports gastrointestinal motility. This combination is used in selected gastrointestinal conditions under the guidance of a healthcare professional. CDSCO records the 20 mg Rabeprazole Sodium and 75 mg Levosulpiride combination in capsule form.
For related gastrointestinal formulations and other pharmaceutical products, explore the Medhexa Pharma product range.
Therapeutic Segment
Gastrointestinal Care | Acid-Related Disorders | GERD Management | Proton Pump Inhibitors | Prokinetic Therapy
Uses of RABIMEXA-LSR
RABIMEXA-LSR may be prescribed for selected acid-related gastrointestinal conditions, particularly where acid suppression and gastrointestinal motility support are considered appropriate.
Potential clinical uses may include:
- Gastroesophageal reflux disease (GERD)
- Acid reflux and associated heartburn
- Acid-related upper gastrointestinal symptoms
- Selected gastrointestinal conditions involving impaired motility
- Conditions where a healthcare professional considers combined PPI and prokinetic therapy appropriate
Rabeprazole itself is a proton pump inhibitor used in adults for conditions including GERD and other acid-related disorders.
The exact indication should depend on the patient’s diagnosis and the prescribing healthcare professional’s assessment.
Key Benefits of RABIMEXA-LSR
RABIMEXA-LSR combines two active ingredients with complementary gastrointestinal actions:
- Rabeprazole Sodium 20 mg helps suppress gastric acid secretion.
- Levosulpiride 75 mg SR provides gastrointestinal motility support.
- The enteric-coated Rabeprazole component helps protect the medicine from degradation in the acidic stomach environment.
- The sustained-release Levosulpiride component provides modified drug release.
- The combination provides acid suppression together with prokinetic support.
- The capsule dosage form allows convenient oral administration.
- Supplied in 10 × 10 ALU-ALU packaging.
The specific 20 mg Rabeprazole Sodium + 75 mg sustained-release Levosulpiride combination is documented in Indian regulatory material.
How RABIMEXA-LSR Works
Rabeprazole belongs to the proton pump inhibitor (PPI) class. It suppresses gastric acid secretion by inhibiting the H⁺/K⁺-ATPase proton pump in gastric parietal cells. This blocks the final stage of gastric acid secretion and reduces gastric acidity.
Levosulpiride has dopamine-receptor blocking activity and can support upper gastrointestinal motility. Its prokinetic action complements the acid-suppressing activity of Rabeprazole.
Therefore, RABIMEXA-LSR combines gastric acid suppression with gastrointestinal motility support.
Common Side Effects of RABIMEXA-LSR
Some patients may experience side effects while taking Rabeprazole or Levosulpiride.
Possible effects include:
- Headache
- Nausea
- Abdominal discomfort
- Diarrhea
- Constipation
- Flatulence
- Dizziness
- Dry mouth
- Fatigue
- Restlessness
Levosulpiride may also cause hormonal or neurological effects in some patients because of its dopamine-blocking activity.
Side effects can vary between individuals. Contact a healthcare professional if symptoms persist, become severe or cause unusual changes.
Important Safety Information
RABIMEXA-LSR should be used only under the guidance of a qualified healthcare professional.
Before taking this medicine, inform your healthcare professional about any history of:
- Movement disorders
- Seizures
- Gastrointestinal obstruction
- Gastrointestinal bleeding
- Significant liver disease
- Other neurological or gastrointestinal conditions
Levosulpiride may cause movement-related effects in susceptible individuals. Report unusual muscle movements, tremors, stiffness, severe restlessness or other abnormal neurological symptoms promptly.
Also tell your healthcare professional about all medicines and supplements you take. Medicines that affect dopamine pathways or the central nervous system may require additional consideration.
Rabeprazole can interact with certain medicines and can affect the absorption of medicines whose bioavailability depends on gastric acidity. Its prescribing information also includes important interaction considerations for medicines such as methotrexate at high doses, warfarin and certain antiretroviral medicines.
Long-term PPI treatment may be associated with effects such as vitamin B12 deficiency, low magnesium levels and certain bone-related risks. Therefore, prolonged treatment should remain under appropriate medical supervision.
Patients with liver or kidney problems should inform their healthcare professional before using RABIMEXA-LSR.
Pregnant or breastfeeding patients should seek medical advice before taking this medicine.
Dosage & Administration
Take RABIMEXA-LSR exactly as prescribed by your healthcare professional.
The appropriate dose and treatment duration depend on the patient’s condition, response to treatment and the applicable prescribing information.
Swallow the capsule whole with water. Do not crush or chew the capsule, as the formulation contains enteric-coated and sustained-release components.
Rabeprazole delayed-release formulations are generally administered according to condition-specific prescribing instructions, and the healthcare professional should determine the appropriate timing for the combination product.
Do not increase the dose, extend treatment or combine RABIMEXA-LSR with another Levosulpiride-containing medicine without medical advice.
Storage
Store RABIMEXA-LSR in a cool, dry place away from excessive heat, moisture and direct sunlight.
Keep the capsules in their original ALU-ALU packaging until use.
Follow the specific storage conditions printed on the product packaging.
Keep out of reach of children.
